{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:45:10Z","timestamp":1778939110232,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.eimc.2019.12.017","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T23:11:50Z","timestamp":1582067510000},"page":"306-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic\/pharmacodynamic perspective"],"prefix":"10.1016","volume":"38","author":[{"given":"Alicia","family":"Rodr\u00edguez-Gasc\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaia","family":"Aguirre-Qui\u00f1onero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Canut-Blasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2019.12.017_bib0160","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2019.12.017_bib0165","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.ajem.2018.08.016","article-title":"Pyelonephritis in the community emergency department: cephalosporins vs. first-lines agents","volume":"36","author":"Vogler","year":"2018","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.eimc.2019.12.017_bib0170","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.eimc.2016.11.005","article-title":"Executive summary of the diagnosis and treatment of urinary tract infection: guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)","volume":"35","author":"de Cueto","year":"2017","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2019.12.017_bib0175","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0924-8579(02)00105-X","article-title":"Correlation between pharmacokinetic\/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection","volume":"19","author":"Frimodt-M\u00f8ller","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eimc.2019.12.017_bib0180","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/AAC.44.1.156-163.2000","article-title":"Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies","volume":"44","author":"Hvidberg","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2019.12.017_bib0185","first-page":"15","article-title":"Relevance in the emergency department of a decisional algorithm for outpatient care of women with acute pyelonephritis","volume":"6","author":"Elkharrat","year":"1999","journal-title":"Eur J Emerg Med"},{"key":"10.1016\/j.eimc.2019.12.017_bib0190","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1553-2712.2008.00070.x","article-title":"The effects of an institutional care map on the admission rates and medical costs in women with acute pyelonephritis","volume":"15","author":"Kim","year":"2008","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.eimc.2019.12.017_bib0195","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2019.12.017_bib0200","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijantimicag.2007.10.024","article-title":"Monte Carlo simulation describing the pharmacodynamic profile of cefditoren in plasma from healthy volunteers","volume":"31","author":"Granizo","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eimc.2019.12.017_bib0205","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/jac\/dkq289","article-title":"Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?","volume":"65","author":"Chisholm","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2019.12.017_bib0210","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1128\/AAC.28.4.504","article-title":"Pharmacokinetics and bactericidal activity of cefuroxime axetil","volume":"28","author":"Ginsburg","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2019.12.017_bib0215","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/jac\/31.3.413","article-title":"Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function","volume":"31","author":"Konishi","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2019.12.017_bib0220","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/j.1875-9114.1997.tb03684.x","article-title":"Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers","volume":"17","author":"Nix","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.eimc.2019.12.017_bib0225","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1128\/AAC.00054-09","article-title":"New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics","volume":"53","author":"Bulitta","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2019.12.017_bib0230","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.diagmicrobio.2010.02.013","article-title":"Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study","volume":"67","author":"Cuevas","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.eimc.2019.12.017_bib0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2015.08.019","article-title":"Comparative in vitro activity of oral antimicrobial agents against Enterobacteriaceae from patients with community-acquired urinary tract infections in three European countries","volume":"22","author":"Kresken","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimc.2019.12.017_bib0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2019.12.017_bib0245","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug\u2019","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.eimc.2019.12.017_bib0250","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2019.12.017_bib0255","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/01.inf.0000094940.81959.14","article-title":"Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation","volume":"22","author":"Bradley","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.eimc.2019.12.017_bib0260","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcrc.2018.11.016","article-title":"Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK\/PD target attainment","volume":"50","author":"Barrasa","year":"2019","journal-title":"J Crit Care"},{"key":"10.1016\/j.eimc.2019.12.017_bib0265","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1128\/AAC.04421-14","article-title":"Propensity-matched analysis to compare the therapeutic efficacies of cefuroxime as initial antimicrobial therapy for community-onset complicated nonobstructive acute pyelonephritis due to Enterobacteriaceae infection in women","volume":"59","author":"Chang","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2019.12.017_bib0270","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1093\/jac\/dku195","article-title":"Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures","volume":"69","author":"Carlier","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2019.12.017_bib0275","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1542\/peds.104.1.79","article-title":"Oral versus initial intravenous therapy for urinary tract infections in young febrile children","volume":"104","author":"Hoberman","year":"1999","journal-title":"Pediatrics"},{"key":"10.1016\/j.eimc.2019.12.017_bib0280","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/1471-2334-12-228","article-title":"Cefditoren: comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients","volume":"12","author":"Hatzaki","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.eimc.2019.12.017_bib0285","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/jac\/dkm115","article-title":"Effects of human albumin and serum on the in vitro bactericidal activity of cefditoren agains penicillin-resistant Streptococcus pneumoniae","volume":"60","author":"Sevillano","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2019.12.017_bib0290","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/jac\/dkl387","article-title":"Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model","volume":"58","author":"Firsov","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2019.12.017_bib0295","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/jac\/dkp371","article-title":"In vitro effect of physiological concentrations of human albumin on the antibacterial activity of tigecycline","volume":"64","author":"Alou","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2019.12.017_bib0300","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ijid.2012.07.009","article-title":"A porspective, randomized, double dummy, placebo-controlled trial of oral cefditoren pivoxil 400mg once daily as switch therapy after intravenous ceftriaxone in the treatment of acute pyelonephritis","volume":"16","author":"Monmaturapoj","year":"2012","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.eimc.2019.12.017_bib0305","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jac\/dkw424","article-title":"Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: multicenter, randomized, open-label trial","volume":"72","author":"Sadahira","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2019.12.017_bib0310","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/jac\/dkm536","article-title":"Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic\u2013pharmacodynamic models with Monte Carlo simulation","volume":"61","author":"Frei","year":"2008","journal-title":"J Antimicrob Chemother"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X20300124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X20300124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:05:34Z","timestamp":1759323934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X20300124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0213005X20300124"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2019.12.017","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are oral cefuroxime axetil, cefixime and cefditoren pivoxil adequate to treat uncomplicated acute pyelonephritis after switching from intravenous therapy? A pharmacokinetic\/pharmacodynamic perspective","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2019.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}